CUPID-A (12+ YEARS)
UAS7 - WEEKLY DISEASE ACTIVITY
(UAS7=ISS7 + HSS7; Week 12 and Week 24, secondary endpoints)1,2
Mean UAS7 at baseline—DUPIXENT: 32.10 (SD, 7.01); placebo: 30.76 (SD, 8.19).2
CUPID-C (12+ YEARS)
vs 32% reductiona in UAS7 at Week 24
(DUPIXENT: -15.61 vs placebo: -11.27; P=0.0324, secondary endpoint)1,2
- 36% vs 27% reductiona in UAS7 at Week 12 (DUPIXENT: -12.59 vs placebo: -9.65, secondary endpoint; not significant)2
- Mean UAS7 at baseline: DUPIXENT (n=73): 28.48 (SD, 7.10); placebo (n=75): 27.86 (SD, 7.82)2
Definitive conclusions cannot be made for Week 12 as the analysis was not multiplicity controlled.
aLSM change from baseline.
Use of DUPIXENT for the CSU indication in patients aged 2-11 years is supported by evidence from two studies of DUPIXENT in CSU patients 12+ years of age.1
CUPID-A AND CUPID-C (12+ YEARS)
In a post hoc pooled analysis of CUPID-A and CUPID-C, improvement in UAS7:
Was observed as early as Week 3
- 32% vs 23% reduction from baseline, respectively2
Mean UAS7 at baseline—DUPIXENT: 30.23 (SD, 7.26); placebo: 29.24 (SD, 8.10).2
Definitive conclusions cannot be made as this was a post hoc analysis which was not multiplicity controlled.
Significantly more patients were urticaria-free at Week 24
CUPID-A (12+ YEARS)
aP=0.0133; OR (95% CI): 3.09 (1.24, 7.69).
bP=0.0034; OR (95% CI): 3.23 (1.43, 7.27).
CUPID-C (12+ YEARS)
≈1.8x
as many patients were urticaria-free (UAS7=0) at Week 24
30% on DUPIXENT (n=73) vs 17% on placebo (n=75; P=0.0165; secondary endpoint)1,2,c
≈1.7x
as many patients had well-controlled symptoms (UAS7≤6) at Week 24
40% on DUPIXENT (n=73) vs 23% on placebo (n=75; P=0.0062; secondary endpoint)1,2,d
cOR (95% CI): 2.73 (1.15, 6.50).
dOR (95% CI): 3.05 (1.32, 7.02).
Improvement in ISS7 and UAS7 at Week 24 with DUPIXENT Across a Broad Range of CSU Patient Types (12+ Years)
in a post-hoc pooled analysis of CUPID A and CUPID C, regardless of1,2:
-
IgE levels
- BMI
- Angioedema
Real CSU patient being treated with DUPIXENT.
Individual results may vary.
See data for itch and hives separately
Urticaria activity score (UAS) is a patient-reported assessment of urticaria severity. UAS7 is the sum of the preceding 7 days’ itch severity score (ISS) and hives severity score (HSS), for a total UAS7 range of 0 to 42.2
ISS7
+
HSS7
=
UAS7
Explore real patients’ experiences with DUPIXENT
BMI, body mass index; CSU, chronic spontaneous urticaria; HSS7, hives severity score over 7 days; ISS7, itch severity score over 7 days; LSM, least squares mean; OR, odds ratio; SD, standard deviation; UAS7, urticaria activity score over 7 days.